Navigation Links
Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development
Date:7/21/2009

NEW YORK, July 21 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded research teams at nine biotech and pharmaceutical companies a total of $3.8 million for pre-clinical Parkinson's drug development projects. Funded investigations aim to push forward novel neuroprotective and improved symptomatic therapies as well as new strategies for addressing complications of treatment.

While MJFF accepts applications from industry under all of its programs, the Therapeutics Development Initiative (TDI) - first launched in 2006 - is the Foundation's only industry-exclusive funding stream. It is a key element of MJFF's strategy to 'de-risk' preclinical PD research for biotech and pharmaceutical companies, thus expanding industry investment in Parkinson's therapeutic development and helping push the most promising research to the next stage.

Projects selected for funding are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants. As with all MJFF grants, full funding is contingent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

Neuroprotective Approaches

Pharmacodynamics of ReS9-S7, a first-in-class, disease-modifying drug candidate for treatment of Parkinson's disease

Gerard Griffioen, PhD, NV reMYND, Leuven, Belgium

Exploring curcumin and curcumin derivatives as putative epigenetic targets of histone deacetylase (HDAC) inhibition in Parkinson's disease

Lawrence Helson, MD, Sign Path Pharma, Inc., Quakertown, Pennsylvania

Assessment of the therapeutic efficacy of progranulin in a sub-chronic animal model of Parkinson's disease

Denis Kay, PhD, Neurodyn, Inc., Charlottetown, Prince Edward Island, Canada

Validation of LRRK2 as a drug target for treatment of Parkinson's disease using antisense technology

Alejandro Lloret, PhD, Isis Pharmaceuticals, Inc., Carlsbad, California

Optimizing lead series of small molecule inhibitors of LRRK2 to deliver tool compounds and clinical development candidates

Alastair D. Reith, PhD, GlaxoSmithKline, United Kingdom

A novel approach to characterize the distribution of a potentially therapeutic dominant-negative inhibitor of tumor necrosis factor in pre-clinical models of PD, and predict the scalability for an effective delivery of therapy in the human brain

Lisa Lynn Shafer, PhD, Medtronic Neuromodulation, Minneapolis, Minnesota

Pre-clinical development of a Parkinson's disease therapy using a glucagon-like peptide (GLP-1) receptor agonist

Kevin Tomaselli, PhD, Amylin Pharmaceuticals, Inc., San Diego, California

Symptomatic Approaches/Complications of Treatment

Effect of novel neuronal nicotonic receptor compounds on treatment of levodopa-induced dyskinesia in Parkinson's disease

Kristen Jordan, PhD, Targacept, Winston-Salem, North Carolina

Optimization of MOR antagonists for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease

Patrick Little, PhD, Adolor Corporation, Exton, Pennsylvania

TDI is launched bi-annually with applications accepted each spring and fall. It has been enthusiastically received by industry researchers. To date the Foundation has awarded $16.5 million total for 33 industry-led projects under the initiative.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. To date, the Foundation has funded $149 million in research. For more information on TDI and the Foundation's industry strategy, please visit www.michaeljfox.org/industry.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Columbia , December 2, 2016 bioLytical Laboratories, ... INSTI HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... BEIJING , Dec. 2, 2016 ... ("Lianluo Smart" or "the Company") which develops, markets ... products in China and ... Cardiovascular Disease Diagnosis and Treatment New Progress Forum, ... Guangdong Province , Guangdong Provincial ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... and Companies" to their offering. ... , , Drug ... market value of drug delivery technologies and the anticancer drugs are ... to organs involved and the types of cancer as well as ...
Breaking Medicine Technology: